Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma

S. Jabbal, A. Manoharan, B. J. Lipworth (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)
    377 Downloads (Pure)


    Background: Tiotropium is a long acting antimuscarinic (LAMA), licenced as triple therapy with inhaled corticosteroid and long acting beta-agonist (ICS/LABA). There may be a synergistic benefit between LAMA and LABA as a consequence of receptor cross-talk, which in turn could modify beta-2 receptor down-regulation and associated tolerance induced by LABA.

    Objective: We hypothesise this mechanism may result in a reduction of airway hyperresponsiveness (AHR) when using triple therapy.

    Methods: We evaluated 14 non-smoking asthmatics using an open-label, randomized crossover design. ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with challenge performed after 1st and last doses at trough.

    Results: We found no significant difference in mannitol sensitivity, expressed as the provocative dose of mannitol required to reach a 15% drop in FEV1, or mannitol reactivity, expressed as the response dose ratio (RDR: max % fall in FEV1 / cumulative dose ) , when comparing ICS/IND/TIO to ICS/IND. Geometric mean fold differences for RDR comparing single and chronic dosing were 3.26 fold (95%CI 1.46-7.29) and 2.51 fold (95%CI 1.32-4.79) for IND and IND/TIO respectively. Furthermore, salbutamol recovery post challenge was significantly blunted after chronic compared to single dosing with either IND (P<0.005) or IND/TIO (P<0.05).

    Conclusion & Clinical Relevance: Our data suggests that concomitant tiotropium does not modify the bronchoprotective tolerance induced by Indacaterol, in turn suggesting that cross-talk may not be clinically relevant when using triple therapy. This study was registered on as NCT02039011.
    Original languageEnglish
    Pages (from-to)1239-1245
    Number of pages7
    JournalClinical and Experimental Allergy
    Issue number10
    Early online date30 Jun 2017
    Publication statusPublished - Oct 2017


    • airway
    • hyperresponsiveness
    • long acting beta 2 agonist
    • Long acting muscarinic antagonist


    Dive into the research topics of 'Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma'. Together they form a unique fingerprint.

    Cite this